Although inhibition of COMT and MAOB enzymes has shown effectiveness in treating PD, significant side effects and limitations are reported, including fluctuation in dopamine levels leading to ON-OFF periods, non-motor symptoms or bradykinesia induced by L-DOPA, and hepatoxicity in the case of entacapone. The gene discussed is MAOB; the disease is Parkinson disease.